With finite natural resources and a growing demand for food, the world must find ways to overcome this challenge. One ...

The pharma giant is betting that Blueprint, whose research revolves around a certain kind of tyrosine kinase, will be a boost ...

Vivodyne, a Penn spinout that creates human tissue to replace animal testing in drug development, has raised $40 million in a second round of venture capital investment. The company, headquartered in ...

The oncology giant will pay $1.5 billion to co-develop a BioNTech drug that targets the proteins PD-L1 and VEGF, following ...

Two groundbreaking biotechnology advances are fundamentally altering human health and food production in 2025, moving from ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection. In March 23andMe said ...

(KRON) — The future of one biotech company on the Peninsula is drastically changing. Unity Biotechnology is laying off its entire workforce, the company announced Monday in a press release.

Unity Biotechnology, a Bay Area company that once won high-profile backers and a $700 million valuation for its research into aging, is now laying off every one of its remaining employees.

The company expects to lay off the majority of its workforce by the end of the second fiscal quarter, according to SEC filings. Mural Oncology is a biotechnology company that focuses on using its ...

Mass firings at the U.S. Food and Drug Administration are particularly risky for small- and mid-cap biotech companies that have innovative treatments in clinical trials but no products on the ...

Turbulence in the capital markets is driving biotechnology startups and venture capitalists to consider strategies such as forming closer ties to large pharmaceutical companies. With optimism ...